Glycotargeting therapeutics

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10821157
APP PUB NO 20160015821A1
SERIAL NO

14627297

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
OXFORD FINANCE LLC AS COLLATERAL AGENT115 SOUTH UNION ST SUITE 300 ALEXANDRIA VA 22314

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gai, Shuning Gland, CH 10 115
Hubbell, Jeffrey A Chicago, US 173 9467
Kontos, Stephane Chavannes-Renens, CH 4 50
Lorentz, Kristen Marie Chavannes-Pres-Renens, CH 7 68
Wilson, David Scott Lausanne, CH 24 205

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 3, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 3, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00